Churchill Capital IX's Latest Deal Raises Questions Amid SPAC Concerns

Churchill Capital IX's latest deal, a $2.2 bln merger with Plus Therapeutics, is intriguing but concerns about SPACs remain due to their spotty track record and recent poor performance. The sponsor's ninth SPAC has had mixed results, with one exception. While the deal may be a positive sign, it's hard to be optimistic about SPACs after the last five years.